Literature DB >> 6175215

Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration.

S B Bressler, N M Bressler, S L Fine, A Hillis, R P Murphy, R J Olk, A Patz.   

Abstract

We divided 96 eyes (93 patients) with senile macular degeneration and choroidal neovascular membranes into two groups--those with juxtafoveal membranes (1 to 250 mu from the center of the foveal avascular zone) and those with subfoveal membranes (0 mu from the center of the zone). After an average follow-up period of 21 months, one of 38 eyes in the juxtafoveal group (3%) had improved two or more lines on the Snellen chart, three eyes (8%) had remained the same, and 34 eyes (89%) had lost two or more lines on the Snellen chart. Although 35 of the 38 eyes (92%) had had initial visual acuities of 6/30 (20/100) or better, 27 eyes (71%) had become legally blind. Of the 58 eyes in the subfoveal group, 18 (31%) had remained the same or improved and 40 (69%) had lost two or more lines on the Snellen chart; 41 (70%) had final visual acuities of 6/60 (20/20) or worse. Of the 26 eyes in the subfoveal group that had had initial visual acuities of 6/60 (20/100) or better (45%). four (15%) had stayed the same and 22 (85%) had lost two or more lines on the Snellen chart. Fourteen of the 26 eyes (54%) had final visual acuities of 6/60 (20/200) or worse. Exudative maculopathy developed in the second eye in 13% of patients who initially had unilateral choroidal neovascularization after 12 months, in 22% after 24 months, and in 29% after 36 months, using life table analysis.

Entities:  

Mesh:

Year:  1982        PMID: 6175215     DOI: 10.1016/0002-9394(82)90410-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  38 in total

1.  A 5-year follow-up study for distance visual acuity after low dose radiation on subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  C Valmaggia; G Ries; P Ballinari
Journal:  Doc Ophthalmol       Date:  2001-11       Impact factor: 2.379

2.  Identification of lesion components that influence visual function in age related macular degeneration.

Authors:  R Hogg; E Curry; A Muldrew; J Winder; M Stevenson; M McClure; U Chakravarthy
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

Review 3.  Development and applications of photo-triggered theranostic agents.

Authors:  Prakash Rai; Srivalleesha Mallidi; Xiang Zheng; Ramtin Rahmanzadeh; Youssef Mir; Stefan Elrington; Ahmat Khurshid; Tayyaba Hasan
Journal:  Adv Drug Deliv Rev       Date:  2010-09-19       Impact factor: 15.470

4.  Fundus autofluorescence in exudative age-related macular degeneration.

Authors:  Vikki A McBain; John Townend; Noemi Lois
Journal:  Br J Ophthalmol       Date:  2006-09-06       Impact factor: 4.638

5.  Indirect photocoagulation of subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  L V Angioletti; P J Colquhoun; A D Kulik; E H Malpica
Journal:  Bull N Y Acad Med       Date:  1991 Jul-Aug

6.  Analysis of monochromatic green argon-laser treatment for age-related macular degeneration.

Authors:  G R Hampton; W V Delaney
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

7.  Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.

Authors:  J N Kirkpatrick; A D Dick; J V Forrester
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

8.  Photocoagulation of choroidal neovascular membranes with a diode laser.

Authors:  M W Ulbig; D A McHugh; A M Hamilton
Journal:  Br J Ophthalmol       Date:  1993-04       Impact factor: 4.638

9.  [Transpupillary thermotherapy for subfoveal choroidal neovascularization. A 9-month follow-up].

Authors:  M Feucht; B Fuisting; G Richard
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

10.  Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study.

Authors:  P T Finger; Y P Gelman; A M Berson; A Szechter
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.